https://scholars.lib.ntu.edu.tw/handle/123456789/535422
標題: | Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study | 作者: | CHEN-HUA LIU WANG-HUEI SHENG HSIN-YUN SUN SZU-MIN HSIEH Lo Y.-C CHUN-JEN LIU TUNG-HUNG SU HUNG-CHIH YANG Liu W.-C PEI-JER CHEN DING-SHINN CHEN CHIEN-CHING HUNG JIA-HORNG KAO |
公開日期: | 2015 | 出版社: | Nature Publishing Group | 卷: | 5 | 起(迄)頁: | 17410 | 來源出版物: | Scientific Reports | 摘要: | Data are limited on the effectiveness and safety of peginterferon plus ribavirin in HIV-infected Asian patients with acute or chronic HCV infection. HIV-infected Taiwanese patients with acute HCV infection received peginterferon plus weight-based ribavirin for 24 weeks (n = 24), and those with chronic HCV genotype 1 or 6 (HCV-1/6) and HCV genotype 2 or 3 (HCV-2/3) infection received response-guided therapy for 12-72 and 24-48 weeks, respectively (n = 92). The primary endpoint was sustained virologic response (SVR), defined as undetectable HCV RNA 24 weeks off-therapy. The SVR rates were 83% and 72% in patients with acute and chronic HCV infection (p = 0.30), and 68% and 72% in patients with chronic HCV-1/6 and HCV-2/3 infection (p = 0.48), respectively. While no factors predicted SVR in acute HCV and chronic HCV-2/3 infection, age (odds ratio [OR] per 1-year increase: 0.88, 95% confidence interval [CI]: 0.78-0.99, p = 0.04), HCV RNA (OR per 1-log10 increase: 0.18, 95% CI: 0.03-0.98, p = 0.03), IL28B genotype (OR: 5.52, 95% CI: 1.55-12.2, p = 0.02), and RVR (OR: 9.62, 95% CI: 3.89-15.3, p = 0.007) predicted SVR in chronic HCV-1/6 infection. In conclusion, the SVR rates of peginterferon plus ribavirin for 24 weeks and for response-guided 12-72 weeks are satisfactory in HIV-infected Taiwanese patients with acute and chronic HCV infection. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984566982&doi=10.1038%2fsrep17410&partnerID=40&md5=2e4d770e540a65529bc59667262ae225 https://scholars.lib.ntu.edu.tw/handle/123456789/535422 |
ISSN: | 2045-2322 | DOI: | 10.1038/srep17410 | SDG/關鍵字: | antivirus agent; interferon; ribavirin; adult; combination drug therapy; female; genetics; genotype; Hepacivirus; hepatitis C; HIV Infections; human; male; middle aged; mixed infection; odds ratio; prospective study; Taiwan; treatment outcome; virology; virus load; Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Odds Ratio; Prospective Studies; Ribavirin; Taiwan; Treatment Outcome; Viral Load |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。